Skip to main content
COO logo

COO · Cooper Companies, Inc.

Track COO — free
$60.74 -0.01 (-0.02%)
Market Cap
$11.55B
Shares
190.16M
Volume · Nov 18 2.2M Avg daily vol (3M) 3.5M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$60.75 Open$60.03 Day$59.26–61.32 52W close$53.27–84.32 Avg vol 30d2.8M Short int10.1M · 5.3% of shares · 3.4d Short vol23% Last earningsSep 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Sep 9

Up next

Dec 3, 2026 Scheduled · in 2 wks

Latest documents

2026
Oct 27
Current report 8-K
CEO White steps down; Rosebrough named interim Executive Chair

Cooper Companies said President and CEO Albert G. White III resigned from the Board and his offices effective October 27, 2026, and will advise the company through April 1, 2027. Walter M. Rosebrough, Jr. was appointed interim Executive Chair while a CEO Search Committee seeks a permanent chief executive. Shlomo Nachman will join the Board December 8, 2026, and three directors will not stand for reelection in 2027.

Director or officer change, or executive pay, Regulation FD disclosure
6 source passages
On October 27, 2026, Albert G. White III resigned from the Board of Directors (the “Board”) of The Cooper Companies, Inc. (the “Company”) and he ceased serving in the offices of President and Chief Executive Officer of the Company. Mr. White has agreed to remain employed full time as a strategic advisor to the Company through April 1, 2027 to assist in the transition of his responsibilities. the Board appointed Walter M. Rosebrough, Jr., an independent member of the Board, as Executive Chair of the Board on an interim basis, effective immediately. The Board has formed a CEO Search Committee, comprised of Lawrence E. Kurzius, Cynthia L. Lucchese and Teresa S. Madden, to oversee the search for a permanent Chief Executive Officer. Shlomo Nachman was appointed to the Board, effective December 8, 2026, to serve until the Company’s 2027 Annual Meeting of Stockholders each of Barbara Carbone, Colleen E. Jay and Robert S. Weiss notified the Company of her or his decision not to stand for reelection as a director at the 2027 Annual Meeting. Open the document at this passage
Sep 9
Quarterly report 10-Q FY2026 Q3, ended Jul 31
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $1.07B ▲ 0.6% Net income $432.8M ▲ 340.3% Diluted EPS $2.24 ▲ 357.1%
Jun 5
Quarterly report 10-Q FY2026 Q2, ended Apr 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.08B ▲ 7.9% Net loss $77.9M Diluted EPS -$0.40
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.24B
Trailing 12 months
Net income (TTM)
$570.30M
Trailing 12 months
Revenue growth YoY
+0.6%
Year over year
Operating margin
12.8%
Trailing 12 months
P / E (TTM)
20.8
Trailing earnings · reciprocal yield 4.8%
FCF yield
5.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$2.39B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.3%
Year over year · fewer shares
Price change (1Y)
-15.9%
Trailing year
Short interest
5.3%
Latest settlement · 3.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Sep 9, 2026
Q3 FY26

TL;DR. Non-GAAP EPS rose 4% to $1.15, free cash flow increased 66% to $273.0 million, and CooperSurgical delivered 3% organic growth alongside expanded buybacks and productivity-driven operating margin improvement. CooperVision remained flat, non-GAAP gross margin declined 60 basis points year over year, and Q4 faces continued inventory effects, lower CooperVision guidance and pressure from investment, foreign exchange and lower tariff refunds.

Bullish
  • + Non-GAAP EPS increased 4% to $1.15 and exceeded consensus expectations for an 11th consecutive quarter.
  • + Free cash flow increased 66% to $273.0 million.
  • + A favorable HMRC examination produced a $307.2 million discrete tax benefit.
  • + CooperSurgical revenue increased 3% organically to $349.2 million.
  • + The share repurchase authorization increased from $2 billion to $3 billion, leaving approximately $1.5 billion available.
  • + Operating margin increased 30 basis points year over year to 26.3% on productivity improvements.
Bearish
  • − CooperVision revenue was flat year over year at $717.0 million.
  • − Non-GAAP gross margin declined 60 basis points year over year because of higher manufacturing costs and unfavorable foreign exchange.
  • − Q4 CooperVision revenue is expected to be down 2% to flat organically.
  • − U.S. channel inventory reduction weighed on Q3 results and will continue to affect Q4.
  • − Greater CooperVision investment, additional foreign-exchange headwinds and lower tariff refunds are expected to pressure Q4 gross and operating margins.
  • − The non-GAAP effective tax rate is expected to rise from roughly 15 and a half this year to roughly 17 and a half in fiscal 2027.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Strong
1-month return +3%
trailing
6-month return −1%
trailing
YTD return −26%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $58 › 200d $68 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +100 funds added
Insider flow Accumulating
Net +$1.9M over 90 days · 0% sells
Short interest Rising
5.32% of shares out · ▲ +11.3% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
652 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth +18%
Y/Y
Gross margin 106%
contracting
EPS growth −5%
Y/Y
Free cash flow $433.7M
Valuation P/E 20.8
below peers
Buyback $1.5B
remaining
Balance sheet $2.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 33%
annualized · 1-yr
Max drawdown −37%
past year
ATR 2.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 7
Latest guidance · from the 8-K filed Sep 9, 2026
Free cash flow objective · fiscal years 2026 through 2028 Non-GAAP at least $2.2B
Long-term free cash flow objective · fiscal years 2026 through 2028 at least $2.2B
Previous outlook earlier release · from the Earnings Call filed Jun 4, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow · 2026 through 2028 $2.2B
Prior guidance period ended · from the 8-K filed Sep 9, 2026
Fiscal fourth quarter 2026 total revenue · Fiscal fourth quarter 2026 $1.06B – $1.08B
CVI revenue · Fiscal fourth quarter 2026 $692M – $706M
CSI revenue · Fiscal fourth quarter 2026 $364M – $374M
Fiscal fourth quarter 2026 non-GAAP diluted EPS · Fiscal fourth quarter 2026 $1.05 – $1.09
Fiscal 2026 total revenue · Fiscal 2026 $4.23B – $4.25B
Fiscal 2026 non-GAAP diluted EPS · Fiscal 2026 $4.51 – $4.55
Guided vs delivered · last 7 settled
Consolidated revenues Q1 fiscal 2026
guided $1.02B – $1.03B
$1.02B In line
Total revenue Fiscal 2024
guided $3.86B – $3.91B
$3.9B In line
Total revenue Fiscal 2023
guided $3.51B – $3.57B
$3.59B Beat +1.5%
Fiscal 2022 total revenue Fiscal 2022
guided $3.26B – $3.33B
$3.31B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $58 › 200d $68 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +100 funds added
Insider flow Accumulating
Net +$1.9M over 90 days · 0% sells
Short interest Rising
5.32% of shares out · ▲ +11.3% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
652 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $53 Now $61 · 24% Range high $84
vs 200-day avg -10% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Free cash flow $273M Third Quarter 2026 —
Non-GAAP diluted EPS non-GAAP $1.15 Third Quarter 2026 —
Non-GAAP gross margin non-GAAP 67% Third Quarter 2026 —
Non-GAAP net income non-GAAP $221.5M Three Months Ended July 31 —
Non-GAAP operating income non-GAAP $280.7M Three Months Ended July 31 —
Non-GAAP operating margin non-GAAP 26% Third Quarter 2026 —
Share repurchases $13.1M the three months ended April 30, 2026 filing —
Shares repurchased 0.2M the three months ended April 30, 2026 filing —
Weighted average price per share $75.84 the three months ended April 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COO
Cooper Companies, Inc.
this stock
$11.55B -25.9% +18.4% 20.8 5.3%
ISRG
Intuitive Surgical Inc
$145.92B -25.7% +20.5% 51.0 2.0%
BDX
Becton Dickinson & Co
$58.86B — +8.2% 95.6 3.0%
MDLN
Medline Inc.
$51.51B -6.8% +11.5% — 2.9%
ALC
Alcon Inc
$36.15B -4.5% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
652
% held
103.6%
Net QoQ
-12.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
610
View
Short & Settlement
Short Interest Rising
Shares short
10.1M
Days to cover
3.4d
Change
+1.0M sh
View
Short Volume
Short vol %
23%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
72.2K
Value
$4.3M
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
46.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$1.9M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Oct 14, 2026
View
Financials
Financials
Revenue (FY)
$4.1B
Net income (FY)
$374.9M
EPS diluted
$1.87
View
Buybacks
Authorized
$3.0B
Remaining
$1.5B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
12

Cooper Companies said President and CEO Albert G. White III resigned from the Board and his offices effective October 27, 2026, and will advise the company through April 1, 2027. Walter M. Rosebrough, Jr. was appointed interim Executive Chair while a CEO Search Committee seeks a permanent chief executive. Shlomo Nachman will join the Board December 8, 2026, and three directors will not stand for reelection in 2027.

View
Proposed Sales
Value
$12.7M
Shares
115.0K
Filed
Sep 19, 2024
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 3, 2026
Last webcast
Sep 9, 2026
View
Investor Relations
Latest news
CooperCompanies Announces Release…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
COO -3.5% +3.0% -0.8% +2.0% -25.9%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +0.4% +8.6% +2.7% +5.4% -33.0%

Capital returns

Latest dividend
$0.0075 / share · ex Jul 26, 2023
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history
Buyback program · as of Sep 9, 2026
Authorized
$3.00B
Spent (derived)
$1.50B
Remaining
$1.50B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 711404 CUSIP 216648501 13F (30d) 647 filings 588 filers Visit website Investor relations